Investigational drug · Phase 3
Deupirfenidone
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Deupirfenidone"
First trial start
2022
Jul 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Deupirfenidone", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis (IPF)
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Deupirfenidone" as an intervention, largest first.
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingRecruiting
PureTechIndustry
NCT07284602 · 1,100 participants (planned) · Start Jun 26, 2026 · Primary completion Nov 2029
Drug: Deupirfenidone; Pirfenidone (PFD) · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Palm Spring, California; Redding, California; Hialeah, Florida · 18 sites in all
- LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingActive, not recruiting
PureTechIndustry
NCT05321420 · 240 participants (planned) · Start Jul 22, 2022 · Primary completion Oct 15, 2024
Drug: Placebo; Pirfenidone and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Los Angeles, California; Newport Beach, California · 103 sites in all
- LYT-100 in Post-acute COVID-19 Respiratory DiseasePivotal-lookingTerminated
PureTechIndustry
NCT04652518 · 185 participants · Start Dec 11, 2020 · Primary completion Jun 28, 2022
Drug: LYT-100 · For: Covid19; Post-acute COVID-19 Respiratory Disease
Sites: Birmingham, Alabama; Florence, Alabama; Los Angeles, California · 31 sites in all
- PK of Deupirfenidone Versus Pirfenidone in Older Healthy SubjectsPivotal-lookingCompleted
PureTechIndustry
NCT07456800 · 116 participants · Start Jul 12, 2021 · Primary completion Jan 1, 2022
Drug: Deupirfenidone; Pirfenidone (PFD) and 1 more · For: Pharmacokinetic Analysis
Sites: Long Beach, California; Lake Mary, Florida; Berlin, New Jersey
- LYT-100 in Patients With BCRLTerminated
PureTechIndustry
NCT04243837 · 50 participants · Start Mar 1, 2020 · Primary completion Sep 9, 2022
Drug: LYT-100 BCRL; Placebo BCRL · For: Breast Cancer Related Lymphoedema; Lymphoedema
Sites: Duarte, California; Los Angeles, California; Maitland, Florida · 8 sites in all
PureTechIndustry
NCT06717100 · 24 participants · Start Dec 17, 2024 · Primary completion Feb 17, 2025
Drug: Nintedanib 150 MG [Ofev] · For: Drug Interactions
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial.
Maher TM, Hamblin MJ, Choi WI, et al. · Am J Respir Crit Care Med 2026
- A phase 1 pharmacokinetics study of deupirfenidone (LYT-100) in healthy older adults.
Maher TM, Chen MC, Korth CC, et al. · ERJ Open Res 2026
- Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications.
Kulkarni T, Santiaguel J, Aul R, et al. · ERJ Open Res 2025
- A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium-Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases.
Chen MC, Korth CC, Harnett MD, et al. · Clin Pharmacol Drug Dev 2022
- Lung Fibrosis after COVID-19: Treatment Prospects.
Bazdyrev E, Rusina P, Panova M, et al. · Pharmaceuticals (Basel) 2021
Also in development for Idiopathic Pulmonary Fibrosis (IPF)
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- INS018_055Phase 32 trials
InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- TDI01Phase 32 trials
Beijing Tide Pharmaceutical Co., Ltd · GVHD, Chronic, Idiopathic Pulmonary Fibrosis (IPF)
- AK3280Phase 31 trial
Shanghai Ark Biopharmaceutical Co., Ltd. · Idiopathic Pulmonary Fibrosis (IPF)
- HB0056Phase 22 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · Asthma, Idiopathic Pulmonary Fibrosis (IPF)
- AGMB-447Phase 21 trial
Agomab Spain S.L.U. · Idiopathic Pulmonary Fibrosis (IPF)
- AP02Phase 21 trial
Avalyn Pharma Inc. · Idiopathic Pulmonary Fibrosis (IPF)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.